Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Celltrion Japan Unveils New List of 5 Biosimilars in Development; Actemra and Pralia and More
Celltrion Healthcare is set to release five biosimilars in the second round of its launch plan for Japan. These will include follow-ons of Eylea (aflibercept) and Stelara (ustekinumab), as well as those for Actemra (tocilizumab), Pralia (denosumab), and Xolair (omalizumab),…
To read the full story
Related Article
- Celltrion Files Biosimilar without Japanese Clinical Data, More Firms Might Follow
October 24, 2025
- Celltrion Set for 6 Biosimilar Filings in 2 Years, Sees Japanese Data Waiver as a Boon
February 6, 2025
- Celltrion Is Developer of Japan’s Third Stelara Biosimilar in the Wings
January 29, 2025
- Celltrion Aims to Market 11 Biosimilars in Japan, Infliximab “Biobetter” in the List
October 3, 2022
BUSINESS
- Recordati Urges Rethink of Zero-Premium Rule on Cost Disclosure
August 31, 2026
- Sumitomo Pharma Goes Global with Adjuvants, Targets 100 Billion Yen
August 31, 2026
- Shionogi to Get US$36.9 Million as US Govt Procures Fetroja
August 31, 2026
- Daiichi’s CD25-Directed ADC DS1025 Enters Clinic
August 31, 2026
- Bayer Files Kerendia in Japan for Broader CKD Use
August 31, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…